Targeted Therapies in Hypertrophic Cardiomyopathy: A Practical Review of Evidence, Implementation, and Innovation [0.03%]
肥厚型心肌病的靶向治疗：证据、实施与创新的实际回顾
Madeline P Smoot,James P MacNamara,Michael P Ayers
Madeline P Smoot
Hypertrophic cardiomyopathy (HCM) is a common inherited disorder characterized by sarcomere dysfunction leading to myocardial hypertrophy, diastolic impairment, and, in many patients can result in dynamic left ventricular outflow tract obst...
Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemia [0.03%]
奥利扎申和普洛扎申：新型apoC-III靶向药物用于治疗高甘油三酯血症
Michael S Kelly,Jelena Lewis,Dylan Zuch et al.
Michael S Kelly et al.
Hypertriglyceridemia is a prevalent lipid disorder associated with residual atherosclerotic cardiovascular disease (ASCVD) risk and increased risk of acute pancreatitis at triglyceride (TG) levels above 1000 mg/dL. Causes of hypertriglyceri...
Asiatic acid mitigates PM2.5-elicited cardiomyocyte pyroptosis via suppression of mtDNA-driven cGAS-STING-NLRP3 signalling [0.03%]
asiatic acid通过抑制mtdna驱动的cgas-sting-nlrp3信号通路缓解pm2.5诱导的心肌细胞焦亡
Zefeng Chen,Xianguan Yu,Leile Tang et al.
Zefeng Chen et al.
Fine particulate matter (PM2.5) is a pervasive air pollutant strongly linked to cardiovascular morbidity, yet effective countermeasures remain elusive. Here, we report that the natural triterpenoid asiatic acid (AA) protects against PM2.5-i...
Efficacy and safety of CETP inhibitors in patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials [0.03%]
针对动脉粥样硬化性心血管病患者的胆固醇酯转运蛋白抑制剂疗效和安全性：随机对照试验的系统评价和meta分析
Román Rodriguez Milán,Magda Sofía Jiménez Castellanos,Adrían Daniel Doníz Viveros et al.
Román Rodriguez Milán et al.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death globally. Cholesteryl ester transfer protein (CETP) inhibitors have been proposed as a novel strategy for cardiovascular risk reduction, yet evidence remains in...
Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock [0.03%]
氟尿嘧啶心肌毒性：一例使用无味尿苷三乙酸酯治疗5-氟尿嘧啶引起的心源性休克的病例及其药理基因组学意义
Simone Filomia,Marco Giuseppe Del Buono,Gianluigi Saponara et al.
Simone Filomia et al.
Fluoropyrimidines, including 5-fluorouracil and capecitabine, are widely used antimetabolite agents and remain central to the treatment of several solid tumors, particularly gastrointestinal malignancies. However, they are a well-establishe...
Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases [0.03%]
整合孟德尔随机化和FAERS数据库分析揭示麦角胺与主动脉和二尖瓣疾病之间的关联
Meng Zhao,Jian Wang,Hanchao Feng et al.
Meng Zhao et al.
To identify potential agents associated with the development of valvular heart diseases (VHD), we employed Mendelian randomization and colocalization analyses to pinpoint genes significantly linked to VHD. A total of 324 genes were found to...
Madelyn Hurwitz,Anandita Kulkarni,Francoise A Marvel et al.
Madelyn Hurwitz et al.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a key component of lipid-lowering therapies for atherosclerotic cardiovascular disease risk management in high-risk primary and secondary prevention populations. PCSK9 mon...
SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study [0.03%]
钠葡萄糖共转运蛋白2抑制剂与脂蛋白(a)水平升高型慢性肾脏病患者疾病进展的关联：一项真实世界队列研究
Abdul Rasheed Bahar,Yasemin Bahar,Ishaq Khoury et al.
Abdul Rasheed Bahar et al.
Elevated lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular disease and may accelerate chronic kidney disease (CKD) progression. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated renal protective effects, but...
Myra Lewontin,Antonio Abbate,Todd C Villines et al.
Myra Lewontin et al.
Low-dose aspirin has a well-established role in secondary prevention of cardiovascular disease but use in primary prevention remains uncommon due to limited evidence of benefit and risk of adverse effects such as bleeding. While benefit of ...
GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment [0.03%]
肥胖与2型糖尿病GLP-1基因治疗临床试验：慢性疾病治疗新范式的探索
Ghadir Amin,Babbette LaMarca,George W Booz
Ghadir Amin